Market News Latest

Diabetic Peripheral Neuropathy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Diabetic Peripheral Neuropathy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 09
13:04 2021
Diabetic Peripheral Neuropathy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Diabetic Peripheral Neuropathy -Pipeline Insights, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Diabetic Peripheral Neuropathy Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Diabetic Peripheral Neuropathy pipeline landscapes. 

The report comprises Diabetic Peripheral Neuropathy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Diabetic Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Diabetic Peripheral Neuropathy pipeline products.    

 

Diabetic Peripheral Neuropathy Overview

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the  symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of  other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there  are often motor features with advancing disease.

It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability.

Some of the key takeaways from the Diabetic Peripheral Neuropathy Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Helixmith, WinSanTor, Regenacy Pharmaceutical, Aptinyx, Eli Lilly and Company, Lexicon Pharmaceuticals, etc., are developing therapies for the treatment of Diabetic Peripheral Neuropathy.

  • Emerging therapies such as VM202, WST-057, Ricolinostat, NYX-2925, LY3016859, LX9211, are expected to have a significant impact on the  Diabetic Peripheral Neuropathy market in the coming years.

Get an overview of pipeline landscape @ Diabetic Peripheral Neuropathy Clinical Trials Analysis 

Diabetic Peripheral Neuropathy Pipeline Therapies along with Key Players:

  1. VM202: Helixmith

  2. WST-057: WinSanTor

  3. Ricolinostat: Regenacy Pharmaceutical

  4. NYX-2925: Aptinyx

  5. LY3016859: Eli Lilly and Company

  6. LX9211: Lexicon Pharmaceuticals

Scope of Diabetic Peripheral Neuropathy Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Helixmith, WinSanTor, Regenacy Pharmaceutical, Aptinyx, Eli Lilly and Company, Lexicon Pharmaceuticals, and others.

  • Pipeline Therapies: VM202, WST-057, Ricolinostat, NYX-2925, LY3016859, LX9211, and others.

Table of Contents

1

Diabetic Peripheral Neuropathy Report Introduction

2

Diabetic Peripheral Neuropathy Executive Summary

3

Diabetic Peripheral Neuropathy Overview

4

Diabetic Peripheral Neuropathy- Analytical Perspective In-depth Commercial Assessment

5

Diabetic Peripheral Neuropathy Pipeline Therapeutics

6

Diabetic Peripheral Neuropathy Late Stage Products (Phase II/III)

7

Diabetic Peripheral Neuropathy Mid Stage Products (Phase II)

8

Diabetic Peripheral Neuropathy Early Stage Products (Phase I)

9

Diabetic Peripheral Neuropathy Preclinical Stage Products

10

Diabetic Peripheral Neuropathy Therapeutics Assessment

11

Diabetic Peripheral Neuropathy Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Diabetic Peripheral Neuropathy Key Companies

14

Diabetic Peripheral Neuropathy Key Products

15

Diabetic Peripheral Neuropathy Unmet Needs

16 

Diabetic Peripheral Neuropathy Market Drivers and Barriers

17

Diabetic Peripheral Neuropathy Future Perspectives and Conclusion

18

Diabetic Peripheral Neuropathy Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Diabetic Peripheral Neuropathy Drugs Pipeline Report.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/